# Pembrolizumab in First-Line Treatment of Advanced-Stage Classical Hodgkin Lymphoma

> **NCT06045195** · PHASE2 · NOT_YET_RECRUITING · sponsor: **University of Cologne** · enrollment: 40 (estimated)

## Conditions studied

- Hodgkin Lymphoma

## Interventions

- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT06045195
- **Lead sponsor:** University of Cologne
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-08
- **Primary completion:** 2027-01
- **Final completion:** 2029-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06045195

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06045195, "Pembrolizumab in First-Line Treatment of Advanced-Stage Classical Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06045195. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*